eli lilly glp-1 agonist FDA just approved orforglipron (Foundayo), Lilly's oral receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest A new chapter in GLP-1

10.1016/j.coche.2014.12.003 Curr Opin Chem Eng

IF may also enhance metabolic health and strengthen resilience against chronic inflammatory conditions, such as diabetes and cardiovascular diseases, by reducing the accumulation of cellular debris [30]

Autophagy: regulator of cell death

The luteal phase is marked by increasing progesterone production by the corpus luteum, which exerts negative feedback signaling that inhibits GnRH, FSH, and LH release and promotes maturation of the endometrium

The standard treatments are angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor neprilysin inhibitors (ARNIs), sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors), beta-blockers, diuretics, and aldosterone antagonists [27]